GLP-1 Agonists Market Set to Expand Through 2036 as Oral Agents and Multi-Receptor Therapies Reshape Cardiometabolic Care

(Albany, US) September 30, 2026 - DelveInsight's "Glucagon-like Peptide-1 (GLP-1) Agonists Market Size, Target Population, Competitive Landscape and Market Forecast 2036 [https://www.delveinsight.com/report-store/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]" report delivers an in-depth understanding of GLP-1 agonists, the addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the GLP-1 agonists market outlook [https://www.delveinsight.com/report-store/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr], treatment uptake, and competitive landscape

Some of the Key Facts of the GLP-1 Agonists Market Report

*
Type 2 diabetes mellitus accounts for over 85% of all diabetes cases worldwide; as of 2021, approximately 537 million adults were living with diabetes, with about 1.4 million new cases diagnosed annually in the United States.

*
Type 2 diabetes prevalence exceeds 25% among adults over 65 years of age.

*
In August 2025, Novo Nordisk announced FDA approval of WEGOVY as the first GLP-1 receptor agonist for adults with MASH with moderate to advanced fibrosis, excluding cirrhosis.

*
In June 2025, Eli Lilly reported Phase III ACHIEVE-1 results showing oral GLP-1 agonist orforglipron significantly reduced A1C at all doses and induced weight loss at 12 mg and 36 mg versus placebo.

*
In May 2026, MetaVia presented Phase I results for DA-1726, a dual GLP-1/glucagon receptor agonist, showing a mean body-weight reduction of 9.1% by Day 54 at the highest dose.

*
The overall 12-month discontinuation rate for GLP-1 agonists is estimated at 36.5%, with higher rates in patients with obesity alone versus type 2 diabetes, and increased discontinuation linked to younger age, female gender, and higher out-of-pocket costs.

*
Regulatory-approved GLP-1 receptor agonists include TRULICITY, BYETTA/BYDUREON, VICTOZA, OZEMPIC/WEGOVY/RYBELSUS, and MOUNJARO/ZEPBOUND, with a deep late-stage pipeline including orforglipron, survodutide, and retatrutide advancing toward potential approval.

Key GLP-1 Agonists Companies

Novo Nordisk, Eli Lilly, Merck, Nektar, Regeneron, Pfizer, Amgen, Boehringer Ingelheim, MBX Biosciences, Sanofi, AstraZeneca, Veru Inc., Viking Therapeutics, Terns Pharmaceuticals, Eccogene, and others.

Key GLP-1 Agonists Therapies

Saxenda, Enobosarm, VK2735, TERN-601, ECC5004, Orforglipron (LY3502970), Survodutide (BI 456906), Retatrutide (LY-3437943), and others.

The GLP-1 agonists market is expected to grow at a significant CAGR through 2036, driven by rising global prevalence of type 2 diabetes and obesity, expanding label indications into cardiometabolic and hepatic disease, and the advancement of oral and multi-receptor agonist therapies. Continued clinical readouts from major pipeline programs are expected to further shape competitive dynamics over the forecast period.

GLP-1 Agonists Overview

GLP-1 agonists (GLP-1RA, GLP-1DAs, incretin mimetics, or GLP-1 analogs) are a class of therapeutics used in the treatment of type 2 diabetes mellitus and obesity that work by:

*
Mimicking the natural hormone glucagon-like peptide-1 to regulate blood glucose levels

*
Triggering the pancreas to release more insulin and slowing digestion

*
Increasing satiety through direct action on the hypothalamus, reducing food intake and appetite

Other physiological functions include increased glucose uptake in muscle, decreased hepatic glucose production, and neuroprotection. These combined effects often result in meaningful weight loss alongside glycemic control, positioning the class at the center of both diabetes and obesity management.

Get a free sample for the GLP-1 Agonists Market Forecast [https://www.delveinsight.com/report-store/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr], Size & Share Analysis Report: https://www.delveinsight.com/report-store/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

GLP-1 Agonists Market Segmentation

The GLP-1 agonists market report proffers detailed analysis for the study period 2020-2034 segmented into:

*
By Region/Geography: North America (US); Europe (Germany, France, Italy, Spain, and the UK); Asia-Pacific (Japan)

*
By Drugs/Therapies and By Indication

*
By Epidemiology Segmentation: Total prevalent cases of selected indications, total diagnosed cases of selected indications, patients seeking help for selected indications, treated cases of selected indications with GLP-1 agonists

GLP-1 Agonists Treatment Landscape

Approved GLP-1 receptor agonists for glycemic control and weight loss span multiple molecules and routes of administration:

*
Approved for glycemic control: Dulaglutide (SC), exenatide injectable solution/suspension (SC), liraglutide (SC), liraglutide/insulin degludec, lixisenatide/insulin glargine, semaglutide (oral, SC), and tirzepatide (dual GIP/GLP-1 receptor agonist).

*
Approved for weight loss: Semaglutide (SC) and liraglutide (SC), with WEGOVY now also approved for MASH with moderate to advanced fibrosis.

*
Orforglipron (LY3502970) (Eli Lilly) is an oral small-molecule GLP-1 receptor agonist in Phase III development for type 2 diabetes and obesity, with positive ACHIEVE-1 results reported in mid-2025.

*
Survodutide (BI 456906) (Boehringer Ingelheim) is a GCGR/GLP-1 dual agonist in Phase III, having received FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate or advanced fibrosis.

*
Retatrutide (LY-3437943) (Eli Lilly) is a GIP/GLP-1/glucagon receptor triagonist in Phase III, having demonstrated up to 24.2% mean weight reduction at 48 weeks in Phase II studies.

Discover more about therapies set to grab major GLP-1 agonists market share [https://www.delveinsight.com/report-store/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]

GLP-1 Agonists Market Strengths

*
A broad and rapidly expanding base of approved therapies across glycemic control and weight management gives physicians and patients multiple validated treatment options.

*
Real-world uptake data show explosive growth for newer agents - OZEMPIC, WEGOVY, and MOUNJARO user growth rates of 83.9%, 119.2%, and 254.3% per month, respectively - reflecting strong commercial momentum.

*
Label expansion into cardiometabolic and hepatic comorbidities, including MASH, cardiovascular risk reduction, and chronic kidney disease protection, is broadening the addressable patient population well beyond diabetes and obesity.

GLP-1 Agonists Market Opportunities

*
The advancement of oral GLP-1 agonists such as orforglipron offers a needle-free alternative that could meaningfully expand patient access and adherence.

*
High 12-month discontinuation rates (36.5%) point to an unmet need for therapies with improved tolerability, affordability, and long-term persistence, particularly among obesity-only patients.

*
Multi-receptor agonists (dual and triple agonists) targeting GLP-1, GIP, glucagon, and amylin pathways represent a significant opportunity for differentiated, next-generation efficacy in weight loss and metabolic disease.

Scope of the GLP-1 Agonists Market Report

*
Study Period: 2020-2034

*
Forecast Period: 2026-2036

*
Coverage: The US; Germany, France, Italy, and Spain (EU4); the UK; Japan

*
Key Companies: Novo Nordisk, Eli Lilly, Merck, Nektar, Regeneron, Pfizer, Amgen, Boehringer Ingelheim, MBX Biosciences, Sanofi, AstraZeneca, and others

*
Key Therapies: Saxenda, Enobosarm, VK2735, TERN-601, ECC5004, Orforglipron, Survodutide, Retatrutide, and others

*
Market Size Estimate: ~USD XX Million in 2034

*
Analysis Includes: KOL views, SWOT analysis, analyst views, reimbursement, unmet needs, market drivers and barriers, epidemiology and patient pool analysis

To know more about GLP-1 agonists companies [https://www.delveinsight.com/report-store/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr] working in the market

Table of Contents

*
GLP-1 Agonists Market Report Introduction

*
Executive Summary for GLP-1 Agonists

*
SWOT Analysis of GLP-1 Agonists

*
GLP-1 Agonists Market Overview at a Glance

*
GLP-1 Agonists Target Patient Pool Analysis

*
GLP-1 Agonists Market Segmentation and Analysis

*
Regional Analysis of the GLP-1 Agonists Market

*
Country-Specific GLP-1 Agonists Market Analysis

*
Competitive Landscape and Key Company Profiles

*
GLP-1 Agonists Unmet Needs

*
GLP-1 Agonists Emerging Therapies and Pipeline

*
GLP-1 Agonists Market Outlook

*
GLP-1 Agonists Market Access and Reimbursement

*
GLP-1 Agonists Market Drivers

*
GLP-1 Agonists Market Barriers

*
GLP-1 Agonists Recent Developments

*
GLP-1 Agonists Appendix

*
GLP-1 Agonists Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma and diagnostics companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glp1-agonists-market-set-to-expand-through-2036-as-oral-agents-and-multireceptor-therapies-reshape-cardiometabolic-care]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.